John D. Davis
Impact in
- Dermatology top 0.1%
- Dermatology and Skin Diseases
- Infectious Diseases top 1%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- HIV/AIDS drug development and treatment
Papers in
- Dermatology 19
- Dermatology and Skin Diseases 19
- Pharmacology 14
- Pharmacogenetics and Drug Metabolism 14
- Co-authors
- J. Brian Houston (6 shared papers)Mohamed A Kamal (14 shared papers)Adrian Dunne (5 shared papers)Christine R. Xu (12 shared papers)Matthew P. Kosloski (7 shared papers)Leon J Aarons (4 shared papers)A. Thomas DiCioccio (11 shared papers)Pavel Kovalenko (9 shared papers)
- Journals
- CPT Pharmacometrics & Systems Pharmacology (13 papers)Clinical and Translational Science (10 papers)British Journal of Clinical Pharmacology (6 papers)Clinical Pharmacology & Therapeutics (5 papers)The Journal of Clinical Pharmacology (5 papers)
- Partner nations
- United StatesUnited KingdomIreland
In The Last Decade
John D. Davis
118 papers receiving 5.6k citations
John D. Davis's Hit Papers
Peers
Comparison fields: 5 of 87
- Dermatology 1.5k
- Infectious Diseases 1.8k
- Pharmacology 178
- Pharmaceutical Science 139
- Immunology and Allergy 39
Countries citing papers authored by John D. Davis
This map shows the geographic impact of John D. Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John D. Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John D. Davis more than expected).
Fields of papers citing papers by John D. Davis
This network shows the impact of papers produced by John D. Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John D. Davis. The network helps show where John D. Davis may publish in the future.
Co-authors
The 25 scholars most cited alongside John D. Davis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 123 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 Hit paper breakdown → | 2020 | 1284 |
| 2 | REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19 Hit paper breakdown → | 2021 | 482 |
| 3 | Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis Hit paper breakdown → | 2019 | 421 |
| 4 | Conjunctivitis in dupilumab clinical trials Hit paper breakdown → | 2019 | 365 |
| 5 | Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19 Hit paper breakdown → | 2021 | 359 |
| 6 | Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial Hit paper breakdown → | 2020 | 323 |
| 7 | Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study Hit paper breakdown → | 2019 | 217 |
| 8 | 2019 | 172 | |
| 9 | 2019 | 122 | |
| 10 | 2022 | 85 | |
| 11 | 2020 | 70 | |
| 12 | 2023 | 70 | |
| 13 | 2016 | 68 | |
| 14 | 2020 | 60 | |
| 15 | 2015 | 59 | |
| 16 | 2008 | 57 | |
| 17 | Dupilumab: Mechanism of action, clinical, and translational science Hit paper breakdown → | 2024 | 57 |
| 18 | 2009 | 53 | |
| 19 | 2008 | 52 | |
| 20 | 2008 | 52 |
About John D. Davis
John D. Davis is a scholar working on Dermatology, Pharmacology, Infectious Diseases, Pharmaceutical Science and Rheumatology, having authored 123 papers that have together received 5.8k indexed citations. Recurring topics across this work include Dermatology and Skin Diseases (19 papers), Pharmacogenetics and Drug Metabolism (14 papers), Lipoproteins and Cardiovascular Health (8 papers), HIV/AIDS drug development and treatment (8 papers), Drug Solubulity and Delivery Systems (7 papers), Cancer Immunotherapy and Biomarkers (6 papers), COVID-19 Clinical Research Studies (4 papers) and SARS-CoV-2 and COVID-19 Research (4 papers). The work is most often cited by research in Dermatology (1.5k citations), Infectious Diseases (1.8k citations), Pharmacology (178 citations), Pharmaceutical Science (139 citations) and Immunology and Allergy (39 citations). John D. Davis has collaborated with scholars based in United States, United Kingdom and Ireland. Frequent co-authors include J. Brian Houston, Mohamed A Kamal, Adrian Dunne, Christine R. Xu, Matthew P. Kosloski, Leon J Aarons, A. Thomas DiCioccio, Pavel Kovalenko, Paul J. Fielder and Manoli Vourvahis. Their work appears in journals such as CPT Pharmacometrics & Systems Pharmacology, Clinical and Translational Science, British Journal of Clinical Pharmacology, Clinical Pharmacology & Therapeutics and The Journal of Clinical Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.